Skip to main content
  • Accessibility
  • Headlines
  • Coronavirus-News
  • Get-Hooked
  • Technology
  • Education
  • Employment
  • Parasports
  • Ask Bhavna
  • NHBrandView
  • Independent Living
  • Lifestyle
  • NH Videos
×
Newz Hook – Changing Attitudes towards Disability Logo
  • Stories
  • Videos
  • Inclusive
  • NH Voice
  • Login
COVID-19 Notification by Government in Accessible Format

Accessibility Tools

Text Size:

Contrast Scheme:

  • C
  • C

Reset

  • Home
  • Get-hooked
  • Understanding the needs of people with Spinal Muscular Atrophy (SMA) – Eleanor Beidatsch

Understanding the needs of people with Spinal Muscular Atrophy (SMA) – Eleanor Beidatsch

Eleanor Beidatsch is seated on a wheelchair
Get-hooked August 30, 2021
  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)

August is Spinal Muscular Atrophy (SMA) Awareness Month. SMA is a genetic disorder characterized by weakness and wasting (atrophy) in muscles used for movement and affects one in 8,000 to 10,000 people worldwide. in this special guest column, Australian scientist Eleanor Beidatsch talks about her experiences living with the condition.

August is recognised internationally as SMA Awareness Month, a time to acknowledge the experiences and struggles of those of us who live with the disability and the caregivers who support us.

In spite of the lack of a cure, recent scientific advances have led to the development of four treatments for most types of Spinal Muscular Atrophy or SMA, a rare genetic condition that is often fatal. SMA affects the nervous system, causing muscle weakness and difficulty breathing and swallowing. The body does this by limiting its production of a protein called survival of motor neuron, or SMN, which is necessary for muscular strength.

Types of SMA

There are four types of SMA, with Type 0 being the most severe, where babies usually die before birth or shortly after.

Type 1 is next in severity, and most people who have it don’t survive beyond their second birthday.

In the early 90s, I was diagnosed with SMA Type 1 as an infant, and I am one of the rare ones who have lived to adulthood. Life expectancy for babies diagnosed with SMA has increased since the development of drug therapies, and the condition is less likely to degenerate as they age.

That’s what makes the death of baby Rosie Dark, just a few days before August, even more tragic. Five-and-a-half months old, Rosie died from SMA Type 1.

Rosemary was from Katanning, a rural town in southwest Western Australia not far from where I live.
It shocked me to read about Rosie, a young child with SMA who lived so close to me and died tragically young.
The reason why Rosie died was a much greater shock to me.

It was reported by the ABC that Rosie’s parents chose not to get her treatment because it was too late for it to help. According to the article, she would need to be diagnosed at just a few weeks old for any possible drug therapy to reduce the need for a power wheelchair, feeding tube, or ventilator.

In most cases, SMA patients will need a power chair as well as a respirator to support their breath throughout their lives. It has been my experience, but the treatments do help, even though I am 27 years old. I was inspired to share my experience after reading about the Dark family’s loss to help others who are facing a future with SMA make informed decisions.

Although the four drugs are mostly used in babies, they are also effective in children and young adults and are available up to the age of 18.

SMA is treated by three gene therapy drugs: Spinraza, Zolgensma, and Risdiplam, as well as Celebrex, a common painkiller that you wouldn’t think, would have an effect on SMA.

Despite the lack of research, I began taking small doses of Celebrex on prescription in 2017 and noticed clear improvements in my strength, dexterity, and breathing. Since late last year, I’ve been taking Risdiplam, an oral drug used for the rest of a person’s life, every day.

Normally, it’s restricted to people under 18, but I got it in a drug trial. After one year of daily use, Risdiplam has shown significant improvements in muscle function in 41% of patients. In my own experience, I have noticed an increase in strength and energy levels since starting the program, as well as improvements to my swallowing and breathing. To maintain as much strength as possible, I use both treatments.

The most widely used medication, Spinraza, has shown to improve muscle strength in 40% of those who receive it. The drugs are administered through regular spinal injections and are also administered to a person for their entire lifetime.

Zoolgensma is given as a one-time treatment through a catheter in the arm and is only available for children up to the age of two.

There is a problem with receiving SMA therapies, of course. Those drugs are very expensive, Spinraza’s yearly cost is $375,000, and Risdiplam’s cost is about $340,000.

In most countries, Celebrex is available on prescription regardless of age and is much cheaper.

So, if you or your child gets a diagnosis of SMA after the first few weeks of life, don’t lose heart because there are lots of options. You can always try Celebrex if the other treatments aren’t available, it’s actually quite effective.

Also Read:

  • Scientist Eleanor Beidatsch aims to shape attitudes towards disability as a science communicator

Support us to make NewzHook Sustainable – Make a Contribution Today

We need your continued support to enable us work towards Changing Attitudes towards Disability. Help us in our attempt to share the voices of people with disabilities that enable them to participate in the society on an equal footing!

Contribute to Newz Hook

NH Videos

Healing pain through art - Dr. Anubha Mahajan, Founder Chronic Pain India

Contribue to Newz Hook |Disability news. Support us to make NewzHook Sustainable – Make a Contribution Today.

Newsletter

 Subscribe to our Newsletter

Want to feature disability stories or share disability news with the disabled community? Write to:

editor@newzhook.com

Newz Hook - Accessible News

Download App Now!

Videos

View More

Accessibility

Visually impaired kids at Ramakrishna Mission Blind Boys Academy bring to life Durga Puja magic in vivid ways

Get-hooked

#LovePossible - Newlyweds Shilpa & Danish Mahajan are setting serious couple goals

Get-hooked

#ChampionsWithCP - Find out what makes movie critic Paresh C Palicha the last word on Malayalam cinema

Get-hooked

#RareDiseases - Coping with Duchenne Muscular Dystrophy powers Karan's passion to help others

Newz Hook Logo

About Newz Hook

Newz Hook | Disability News - media site focusing on Disability Stories and Changing Attitudes towards Disability globally. We highlight disability news, offer inclusive solutions and create accessible collaborations. Our focus is to have Inclusion Champions from across the globe who will share disability stories and news.
Lets come together to change attitudes towards disability!

Newz Hook is reader-supported. When you buy through links on our site, we may earn an affiliate commission.

Follow us on:

Related Links

  • About Us
  • Contact Us
  • Privacy Policy
  • Partner with Newz Hook
  • Embed Newz Hook Timeline
  • Affiliate disclosure
  • Accessibility Statement
  • Contribute to Newz Hook

Our Awards

Zero Project Award Winner 2018
Back To Top
© 2019 All Right Reserved. Inclusive News India Private Limited.

Ask Bhavna

All fields are mandatory unless specified as optional.